ACR appropriateness criteria® postradical prostatectomy irradiation in prostate cancer

Carl J. Rossi, I. Chow Joe Hsu, May Abdel-Wahab, V. Elayne Arterbery, Jay P. Ciezki, Steven J. Frank, Noah Hahn, Brian J. Moran, Seth A. Rosenthal, Gregory Merrick

Research output: Contribution to journalArticle

Abstract

The role of postradical prostatectomy radiation therapy continues to evolve under the influence of new clinical data. In particular, 2 recently published or updated randomized trials have prompted a reevaluation of its utility in the adjuvant and salvage setting. The Southwest Oncology Group 8794 trial randomized 473 patients with stage T3a-T3b disease to adjuvant radiotherapy versus observation. With a median follow-up of 12.7 years, this trial demonstrates an improvement in metastasis-free (93/214 vs. 114/211, P = 0.016) and overall survival (88 vs. 110 deaths, P = 0.023) favoring adjuvant radiotherapy. The European Organization for Research and Treatment of Cancer 22911 study of 972 patients with at least 1 "high risk" feature at surgery (extracapsular extension, positive surgical margins, seminal vesicle involvement) randomized to immediate adjuvant radiotherapy (60 Gy) versus observation. The freedom from biochemical failure at 5 years was 53% in the observation alone group versus 74% in the adjuvant radiotherapy group (P <0.0001). This review summarizes the current evidence-based literature supporting the use of postradical prostatectomy radiation therapy in various common clinical settings and will serve to illustrate the appropriateness of postoperative radiotherapy by reviewing its implementation in a variety of commonly occurring clinical scenarios. It is intended to serve both as a guideline for the practicing radiation oncologist and a resource for further learning.

Original languageEnglish (US)
Pages (from-to)92-98
Number of pages7
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume34
Issue number1
DOIs
StatePublished - Feb 2011
Externally publishedYes

Fingerprint

Adjuvant Radiotherapy
Prostatectomy
Prostatic Neoplasms
Radiotherapy
Observation
Seminal Vesicles
Learning
Organizations
Guidelines
Neoplasm Metastasis
Survival
Research
Neoplasms
Therapeutics

Keywords

  • adjuvant radiotherapy
  • appropriateness criteria
  • prostate cancer
  • radical prostatectomy
  • salvage radiotherapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Rossi, C. J., Joe Hsu, I. C., Abdel-Wahab, M., Arterbery, V. E., Ciezki, J. P., Frank, S. J., ... Merrick, G. (2011). ACR appropriateness criteria® postradical prostatectomy irradiation in prostate cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 34(1), 92-98. https://doi.org/10.1097/COC.0b013e3182005319

ACR appropriateness criteria® postradical prostatectomy irradiation in prostate cancer. / Rossi, Carl J.; Joe Hsu, I. Chow; Abdel-Wahab, May; Arterbery, V. Elayne; Ciezki, Jay P.; Frank, Steven J.; Hahn, Noah; Moran, Brian J.; Rosenthal, Seth A.; Merrick, Gregory.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 34, No. 1, 02.2011, p. 92-98.

Research output: Contribution to journalArticle

Rossi, CJ, Joe Hsu, IC, Abdel-Wahab, M, Arterbery, VE, Ciezki, JP, Frank, SJ, Hahn, N, Moran, BJ, Rosenthal, SA & Merrick, G 2011, 'ACR appropriateness criteria® postradical prostatectomy irradiation in prostate cancer', American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 34, no. 1, pp. 92-98. https://doi.org/10.1097/COC.0b013e3182005319
Rossi, Carl J. ; Joe Hsu, I. Chow ; Abdel-Wahab, May ; Arterbery, V. Elayne ; Ciezki, Jay P. ; Frank, Steven J. ; Hahn, Noah ; Moran, Brian J. ; Rosenthal, Seth A. ; Merrick, Gregory. / ACR appropriateness criteria® postradical prostatectomy irradiation in prostate cancer. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 2011 ; Vol. 34, No. 1. pp. 92-98.
@article{e66d22214872422aaf8e783f2664968a,
title = "ACR appropriateness criteria{\circledR} postradical prostatectomy irradiation in prostate cancer",
abstract = "The role of postradical prostatectomy radiation therapy continues to evolve under the influence of new clinical data. In particular, 2 recently published or updated randomized trials have prompted a reevaluation of its utility in the adjuvant and salvage setting. The Southwest Oncology Group 8794 trial randomized 473 patients with stage T3a-T3b disease to adjuvant radiotherapy versus observation. With a median follow-up of 12.7 years, this trial demonstrates an improvement in metastasis-free (93/214 vs. 114/211, P = 0.016) and overall survival (88 vs. 110 deaths, P = 0.023) favoring adjuvant radiotherapy. The European Organization for Research and Treatment of Cancer 22911 study of 972 patients with at least 1 {"}high risk{"} feature at surgery (extracapsular extension, positive surgical margins, seminal vesicle involvement) randomized to immediate adjuvant radiotherapy (60 Gy) versus observation. The freedom from biochemical failure at 5 years was 53{\%} in the observation alone group versus 74{\%} in the adjuvant radiotherapy group (P <0.0001). This review summarizes the current evidence-based literature supporting the use of postradical prostatectomy radiation therapy in various common clinical settings and will serve to illustrate the appropriateness of postoperative radiotherapy by reviewing its implementation in a variety of commonly occurring clinical scenarios. It is intended to serve both as a guideline for the practicing radiation oncologist and a resource for further learning.",
keywords = "adjuvant radiotherapy, appropriateness criteria, prostate cancer, radical prostatectomy, salvage radiotherapy",
author = "Rossi, {Carl J.} and {Joe Hsu}, {I. Chow} and May Abdel-Wahab and Arterbery, {V. Elayne} and Ciezki, {Jay P.} and Frank, {Steven J.} and Noah Hahn and Moran, {Brian J.} and Rosenthal, {Seth A.} and Gregory Merrick",
year = "2011",
month = "2",
doi = "10.1097/COC.0b013e3182005319",
language = "English (US)",
volume = "34",
pages = "92--98",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - ACR appropriateness criteria® postradical prostatectomy irradiation in prostate cancer

AU - Rossi, Carl J.

AU - Joe Hsu, I. Chow

AU - Abdel-Wahab, May

AU - Arterbery, V. Elayne

AU - Ciezki, Jay P.

AU - Frank, Steven J.

AU - Hahn, Noah

AU - Moran, Brian J.

AU - Rosenthal, Seth A.

AU - Merrick, Gregory

PY - 2011/2

Y1 - 2011/2

N2 - The role of postradical prostatectomy radiation therapy continues to evolve under the influence of new clinical data. In particular, 2 recently published or updated randomized trials have prompted a reevaluation of its utility in the adjuvant and salvage setting. The Southwest Oncology Group 8794 trial randomized 473 patients with stage T3a-T3b disease to adjuvant radiotherapy versus observation. With a median follow-up of 12.7 years, this trial demonstrates an improvement in metastasis-free (93/214 vs. 114/211, P = 0.016) and overall survival (88 vs. 110 deaths, P = 0.023) favoring adjuvant radiotherapy. The European Organization for Research and Treatment of Cancer 22911 study of 972 patients with at least 1 "high risk" feature at surgery (extracapsular extension, positive surgical margins, seminal vesicle involvement) randomized to immediate adjuvant radiotherapy (60 Gy) versus observation. The freedom from biochemical failure at 5 years was 53% in the observation alone group versus 74% in the adjuvant radiotherapy group (P <0.0001). This review summarizes the current evidence-based literature supporting the use of postradical prostatectomy radiation therapy in various common clinical settings and will serve to illustrate the appropriateness of postoperative radiotherapy by reviewing its implementation in a variety of commonly occurring clinical scenarios. It is intended to serve both as a guideline for the practicing radiation oncologist and a resource for further learning.

AB - The role of postradical prostatectomy radiation therapy continues to evolve under the influence of new clinical data. In particular, 2 recently published or updated randomized trials have prompted a reevaluation of its utility in the adjuvant and salvage setting. The Southwest Oncology Group 8794 trial randomized 473 patients with stage T3a-T3b disease to adjuvant radiotherapy versus observation. With a median follow-up of 12.7 years, this trial demonstrates an improvement in metastasis-free (93/214 vs. 114/211, P = 0.016) and overall survival (88 vs. 110 deaths, P = 0.023) favoring adjuvant radiotherapy. The European Organization for Research and Treatment of Cancer 22911 study of 972 patients with at least 1 "high risk" feature at surgery (extracapsular extension, positive surgical margins, seminal vesicle involvement) randomized to immediate adjuvant radiotherapy (60 Gy) versus observation. The freedom from biochemical failure at 5 years was 53% in the observation alone group versus 74% in the adjuvant radiotherapy group (P <0.0001). This review summarizes the current evidence-based literature supporting the use of postradical prostatectomy radiation therapy in various common clinical settings and will serve to illustrate the appropriateness of postoperative radiotherapy by reviewing its implementation in a variety of commonly occurring clinical scenarios. It is intended to serve both as a guideline for the practicing radiation oncologist and a resource for further learning.

KW - adjuvant radiotherapy

KW - appropriateness criteria

KW - prostate cancer

KW - radical prostatectomy

KW - salvage radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=79951644527&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951644527&partnerID=8YFLogxK

U2 - 10.1097/COC.0b013e3182005319

DO - 10.1097/COC.0b013e3182005319

M3 - Article

VL - 34

SP - 92

EP - 98

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 1

ER -